People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

Patients with acromegaly make too much growth hormone, which causes them to grow disproportionately large bones, organs and ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

Acromegaly, for instance, requires a controlled and predictable suppression of growth hormone, which can be best achieved through subcutaneous injection.

Bilateral adrenocortical hyperplasia is often present in acromegaly 10 and has also been produced in animals with administration of growth hormone. 11 The absence of spontaneous signs of ...